Exploring the Long Term Safety, Tolerability and Clinical Effect of Laquinimod

Study Title

An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease

Teva Identifier

LAQ/5063OL | LAQ/5063 | 2005-004334-41

ClinicalTrials.gov Identifier

NCT00745615

Study Status

Terminated

Trial Condition(s)

Relapsing Remitting Multiple Sclerosis

Interventions

Drug: Laquinimod | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

neurology icon for clinical trials

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 50 Years

Trial Duration

December 7, 2005 - July 23, 2017

Phase

Phase 2

Study Type

Interventional